含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习

来源期刊：广州医药 | 70-74 发布时间：2023-02-27 收稿时间：2025/11/13 18:39:05 阅读量：13

作者：: 朱志刚,

钟伟杰,

关键词：: 达雷妥尤单抗多发性骨髓瘤高龄高危; daratumumab multiple myeloma elderly high-risk

DOI：: 10.3969/j.issn.1000-8535.2023.02.014

收稿时间：: 2022-03-07
修订日期：
接收日期：
引用总数：: 1

目的观察达雷妥尤单抗联合来那度胺及地塞米松(DRd)方案巩固治疗序贯达雷妥尤单抗和来那度胺两药维持治疗1例高龄高危初治多发性骨髓瘤患者的疗效、生存时间和不良反应。方法回顾分析广州市第一人民医院老年病科血液肿瘤科2019年3月收治的1例高龄高危初治多发性骨髓瘤患者的临床资料,并复习相关最新文献。结果患者应用伊沙佐米、来那度胺和地塞米松方案诱导治疗13疗程后只达到部分缓解的疗效,未能进一步缓解,且不良反应多且严重,后改为DRd方案巩固治疗2疗程后,达到完全缓解,继续使用达雷妥尤单抗联合来那度胺两药维持治疗,不良反应少,至随访结束总生存期和无进展生存期均为35个月。结论含达雷妥尤单抗方案巩固和维持治疗可能会改善高龄高危初治多发性骨髓瘤患者的预后,延长生存时间,耐受性好。

1、 MOHYUDDIN G R, MIAN H.Daratumumab in newly diagnosed MM-incorporating lessons learnt from CASSIOPEIA, MAIA and beyond[J].Nat Rev Clin Oncol,2022, 19(1):3-4.

2、 MATEOS M, CAVO M, BLADE J, et al.Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial[J].Lancet (London, England),2020, 395(10218):132-141.

3、 FACON T, KUMAR S, PLESNER T, et al.Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial[J].The Lancet Oncology, 2021, 22(11):1582-1596.

4、 SUZUKI K, DIMOPOULOS M A, TAKEZAKO N, et al.Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study[J].Blood Cancer J,2018, 8(4):41.

5、 BAHLIS N J, DIMOPOULOS M A, WHITE D J, et al.Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study[J].Leukemia,2020, 34(7):1875-1884.

6、 USMANI S Z, WEISS B M, PLESNER T, et al.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma[J].Blood,2016, 128(1):37-44.

7、 VIOLA D, DONA A, CASERTA E, et al.Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting[J].Leukemia,2021, 35(1):189-200.

8、 NIJHOF I S, GROEN R W, NOORT W A, et al.Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib[J].Clin Cancer Res,2015, 21(12):2802-2810.

9、 LOKHORST H M, PLESNER T, LAUBACH J P, et al.Targeting CD38 with daratumumab monotherapy in multiple myeloma[J].N Engl J Med,2015, 373(13):1207-1219.

10、 de WEERS M, TAI Y T, van DER VEER M S, et al.Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J].J Immunol,2011, 186(3):1840-1848.

11、 KUMAR S K, BERDEJA J G, NIESVIZKY R, et al.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study[J].Lancet Oncol,2014, 15(13):1503-1512.

12、中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020, 59(5):341-346.

13、杨玉,林彩芹,李春雨,等.1q21扩增对于初治多发性骨髓瘤预后影响的异质性分析[J].临床血液学杂志,2021, 34(09):628-635.

14、 DU C, MAO X, XU Y, et al.1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib[J].Leuk Lymphoma,2020, 61(5):1201-1210.

15、 DERMAN B, KOSURI S, JAKUBOWIAK A.Knowing the unknowns in high risk multiple myeloma[J].Blood Revi,2022(51):100887.

16、 WALLINGTON-BEDDOE C, MYNOTT R.Prognostic and predictive biomarker developments in multiple myeloma[J].J Hematol Oncol,2021, 14(1):151.

17、 COWAN A, GREEN D, KWOK M, et al.Diagnosis and management of multiple myeloma: A review[J].JAMA,2022, 327(5):464-477.

18、万一柯,侯健.复发难治性多发性骨髓瘤治疗的现状与挑战.肿瘤防治研究[J],2019, 49(9):759-765.

1、刘芳洁,宾婷,谢媚,等.监测外周血CD34+细胞计数预测普乐沙福联合G-CSF自体干细胞动员的效果[J].广州医药,2023,54(12):72-77.